Genetic Analysis for Predicting of Relapse During Steroid Treatment for Autoimmune Pancreatitis (AIP)

Sponsor
Asan Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT00444444
Collaborator
(none)
40
1
63.9
0.6

Study Details

Study Description

Brief Summary

To determine whether certain alleles or haplotypes of major histocompatibility complex gene are associated with AIP in Korean population, we undertook this study with high-resolution typing for HLA (sequence-based typing).

Primary outcomes: detection of novel allele associated with AIP in Korean population Secondary outcomes: detection of genetic factor for relapse of AIP during steroid treatment

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Autoimmune chronic pancreatitis (AIP) can be defined as a chronic inflammation of the pancreas due to an autoimmune mechanism; autoimmunity is responsible for producing the pancreatic lesion. AIP is a distinctive type of chronic pancreatitis that shows reversible improvement of pancreatic morphology and function with oral steroid therapy, in comparison to other types of chronic pancreatitis which hardly respond to various treatments. AIP is increasingly being recognized to be a worldwide entity. The sudden increment in cases reported probably reflects the growing awareness of the entity, rather than a rise in the true incidence. In previous Japanese report, HLA DRB10405-DQB0401 haplotype may be associated with autoimmune pancreatitis in the Japanese population. However, to date there was no subsequent data for supporting these results. In addition, this Japanese study had a limitation in methodology by using a low-resolution typing for HLA. Although this entity is well responsive to steroid therapy, relapse of AIP during steroid treatment is not uncommon. Unfortunately, there has been no laboratory or genetic predictor for responsiveness to steroid therapy in patients with AIP. To further clarify and confirm high-risk and protective genotypes for autoimmune diseases, therefore, high-resolution typing for HLA should be needed. Thus, to determine whether certain alleles or haplotypes of major histocompatibility complex gene are associated with AIP in Korean population, we undertook this study with high-resolution typing for HLA (sequence-based typing).

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    40 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Clinical Analysis for Predicting of Relapse During Steroid Treatment for Autoimmune Pancreatitis (AIP) in Korean Population Based on the HLA Analysis by Using a High Resolution (Sequence Based) Techniques
    Study Start Date :
    Feb 1, 2002
    Actual Study Completion Date :
    Jun 1, 2007

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      19 Years to 75 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      Yes
      Inclusion Criteria:
      • Patient with autoimmune pancreatitis

      • The diagnosis is mainly based on the following three characteristic findings proposed by Japan Pancreas Society in 2002: (1)Imaging studies: irregular narrowing of the main pancreatic duct and diffuse enlargement of the pancreas, (2) Laboratory data: elevated serum IgG or the presence of autoantibodies, (3) Histological examinations: fibrotic changes with lymphoplasmacytic infiltration in the pancreatic tissue.

      • Age 18 years and above

      • No serious medical or psychological condition that would preclude study treatment

      • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

      Exclusion Criteria:
      • Age below 18 years

      • Pregnancy

      • Active alcohol or drug abuse

      • Unstable or unwilling to comply with follow up

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center Seoul Korea, Republic of 138-736

      Sponsors and Collaborators

      • Asan Medical Center

      Investigators

      • Study Director: Do Hyun Park, MD, PhD, Soon Chun Hyang University
      • Study Chair: Myung-Hwan Kim, MD, PhD, Asan Medical Center

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00444444
      Other Study ID Numbers:
      • 2007-0038
      First Posted:
      Mar 7, 2007
      Last Update Posted:
      Jun 26, 2007
      Last Verified:
      Mar 1, 2007

      Study Results

      No Results Posted as of Jun 26, 2007